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The chronic effects of metformin on liver gluconeogenesis
involve repression of theG6pc gene, which is regulated by the
carbohydrate-response element–binding protein through
raised cellular intermediates of glucose metabolism. In this
study we determined the candidate mechanisms by which met-
formin lowers glucose 6-phosphate (G6P) in mouse and rat
hepatocytes challengedwith high glucose or gluconeogenic pre-
cursors. Cell metformin loads in the therapeutic range lowered
cell G6P but not ATP and decreased G6pc mRNA at high glu-
cose. The G6P lowering by metformin was mimicked by a com-
plex 1 inhibitor (rotenone) and an uncoupler (dinitrophenol)
and by overexpression of mGPDH, which lowers glycerol
3-phosphate and G6P and also mimics the G6pc repression by
metformin. In contrast, direct allosteric activators of AMPK
(A-769662, 991, andC-13) had opposite effects frommetformin
on glycolysis, gluconeogenesis, and cell G6P. The G6P lowering
by metformin, which also occurs in hepatocytes from AMPK
knockout mice, is best explained by allosteric regulation of
phosphofructokinase-1 and/or fructose bisphosphatase-1, as
supported by increased metabolism of [3-3H]glucose relative to
[2-3H]glucose; by an increase in the lactate m2/m1 isotopolog
ratio from [1,2-13C2]glucose; by lowering of glycerol 3-phos-
phate an allosteric inhibitor of phosphofructokinase-1; and by
marked G6P elevation by selective inhibition of phosphofruc-
tokinase-1; but not by amore reduced cytoplasmicNADH/NAD
redox state. We conclude that therapeutically relevant doses of
metformin lower G6P in hepatocytes challenged with high glu-
cose by stimulation of glycolysis by an AMP-activated protein
kinase–independent mechanism through changes in allosteric
effectors of phosphofructokinase-1 and fructose bisphospha-
tase-1, including AMP, Pi, and glycerol 3-phosphate.
Metformin is themost commonly prescribed drug for lower-
ing blood glucose in type 2 diabetes. Its therapeutic effect
involves inhibition of glucose absorption by the gut and inhibi-
tion of glucose production by the liver (1). Evidence for the
lattermechanism inman is largely derived from chronic studies
demonstrating efficacy after 2–26 weeks therapy (2). Suppres-
sion of hepatic glucose production during chronic therapy may
involve either acute inhibition of gluconeogenic flux or chronic
changes in gene expression (3–5), with various arguments in
support of the latter. One such argument is a lack of acute effect
of intravenously administered metformin on hepatic glucose
production inman (6–8). Studies onmetformin effects on gene
expression in animal and cellular models have largely focused
onmechanismsmediated by activation of AMPK (9). However,
repression by metformin of the G6pc gene, which encodes the
enzyme catalyzing the final reaction in hepatic glucose produc-
tion, has also been observed in hepatocytes from AMPK-defi-
cient mice (10). TheG6pc gene is of particular interest because
it was identified as a component of the metformin mechanism
in both animal diabetes and in man by nontargeted approaches
(11–13) and becauseG6pc is regulated by the transcription fac-
tor ChREBP (14), which is activated by raised cellular phospho-
rylated intermediates of glucose metabolism in conditions of
raised blood glucose or compromised intracellular homeosta-
sis, resulting in raised glucose 6-phosphate, G6P4 (14–17).
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ChREBP recruitment to theG6pc gene promoter is inhibited by
metformin in associationwith lowering of cell G6P and fructose
2,6-P2 (18). Although G6P lowering by metformin has been
shown in liver in vivo (19) and in isolated hepatocytes (18–21),
the underlying mechanisms remain unsettled. The aim of this
study was to identify the mechanism(s) by which metformin
levels corresponding to a therapeutic dose lower G6P in hepa-
tocytes. Such mechanisms are expected to contribute to G6pc
repression by metformin (10, 18). Various sets of evidence sup-
port lowering of G6P by increased glycolysis via allosteric effec-
tors of phosphofructokinase-1.
Results
Cell metformin accumulation
Intracellular accumulation ofmetformin is slower in hepato-
cytes than in liver in vivo (19, 22). Mice given an intragastric
load of 50 mg/kg metformin attain a portal vein metformin
concentration of 50–60 M and accumulate peak metformin
levels in liver of 1–2 nmol/mg protein within 30 min (22). Rat
hepatocytes incubated with 100–200 M metformin accumu-
late cell loads of 1–2 nmol/mg protein after 2 h (18). Through-
out this study on rat andmouse hepatocytes, we used a protocol
comprising a 2-h preincubation with metformin followed by a
1-h incubation with medium containing the substrates and the
same metformin concentration as during the preincubation.
Using this protocol, the cellmetformin content at the end of the
3-h incubationwith 100–200Mmetformin is 1–2 nmol/mg in
mouse hepatocytes (Fig. 1A). This corresponds to an intracel-
lular/extracellular metformin concentration ratio of 5 (Fig.
1B). These data on mouse hepatocytes (Fig. 1, A and B) are
similar to data on rat hepatocytes reported previously (18).
Metformin lowers cell G6Pwhen raised with high glucose or
gluconeogenic precursors
Wedetermined the effects ofmetformin on cell G6P in rat or
mouse hepatocytes incubated with either high glucose (25 mM)
or with dihydroxyacetone (DHA), which enters the glycolytic/
gluconeogenic pathway at the level of triose phosphates, orwith
xylitol, which enters the pathway at triose phosphate and fruc-
tose 6-phosphate (23). These experiments were performed
without or with the chlorogenic acid derivative S4048 (24),
which inhibits the G6P transporter (Slc37a4) on the endoplas-
mic reticulum. S4048 has no effect of G6P levels in hepatocytes
incubated with 5 mM glucose (Fig. 1C), but it enhanced the
elevation by high glucose (25 mM) in rat hepatocytes (Fig. 1D)
andmouse hepatocytes (Fig. 1E). The elevation inG6Pby S4048
in hepatocytes and in vivo (24–26) supports the role of glucose
6-phosphatase in maintaining G6P homeostasis (16, 17). Met-
formin did not lower G6P in hepatocytes incubated with 5 mM
glucose (Fig. 1C), but it loweredG6P dose-dependently in rat or
mouse hepatocytes with 25 mM glucose (Fig. 1, D and E) and
caused a greater fractional lowering when G6P was elevated by
S4048 (Fig. 1, F and G). Similarly metformin lowered G6P with
both DHA (Fig. 1H) and xylitol (Fig. 1I). Cell ATP was
decreased by 1 mM metformin but not by0.5 mM metformin
(Fig. 1, J–N).
AMPK activators do notmimicmetformin on glycolysis,
gluconeogenesis, or cell G6P
We next tested whether direct activators of AMPK
(A-769662, 991, and C-13) mimic the metformin lowering of
G6Pwith high glucose or DHA (Fig. 2). A-769662 and compound
991 bind to a discrete pocket between the  and  subunits of
AMPK (27, 28), whereas C-13 is a prodrug that is metabo-
lized to an “AMP mimetic” that binds to the -regulatory
subunit (29). A-769662 (20 M) caused similar phosphoryla-
tion of the AMPK target acetyl-CoA carboxylase–S79 as 500
M metformin (Fig. 2A), and C-13 and 991 at 3 M caused
comparable phosphorylation as 20 M A-769662 (Fig. 2B).
With 25 mM glucose, A-769662 increased G6P, 991 had no
effect, and C-13 caused amodest decrease compared withmet-
formin (Fig. 2C) with negligible effect onATP (Fig. 2D) butwith
significant inhibition in the production of lactate and pyruvate
unlike metformin (Fig. 2E). With DHA, the AMPK activators
unlike metformin significantly raised G6P (Fig. 2F), with little
effect on ATP (Fig. 2G), and A-769662 and C-13 also increased
glucose production (Fig. 2H). This indicates opposite effects of
AMPK activators from metformin on glycolysis with high glu-
cose and on gluconeogenesis from DHA and shows that the
AMPK activators do not mimic the G6P lowering bymetformin.
A-769662 does notmimic lowmetformin on G6pc and Gck
expression at high glucose
We next tested whether A-769662 mimics metformin (0.2
mM) on gene regulation at high glucose. For these experiments,
we used 45 mM glucose to achieve G6P levels intermediate
between 25 mM glucose alone and 25 mM glucose  S4048.
High glucose caused repression of Gck (by 60%) and induction
of G6pc and Pklr by 5- and 3-fold, respectively (Fig. 2, I–K).
A-769662 caused similar Pklr repression as high metformin
(Fig. 2K) but did not mimic the effect of 0.2 mM metformin on
either Gck or G6pc expression (Fig. 2, I and J). This implicates
AMPK-independent mechanisms for the counter-regulatory
effects of low metformin on G6pc and Gck expression.
Metformin lowers G6P in hepatocytes fromAMPK-KOmice
To test for involvement of AMPK in the metformin mecha-
nism on G6P, we used hepatocytes from liver-specific
AMPK12 knockoutmice.We confirmed the lack of immuno-
activity to AMPK in hepatocytes from AMPK1lox/lox,
2lox/lox–Alfp–Cre (AMPK-KO) compared with the
AMPK1lox/lox,2lox/lox (AMPKlox/lox) controls (Fig. 3A) and
also a lack of immunoactivity to phospho-AMPK after chal-
lenge with metformin or A-769662 (Fig. 3B). To test whether
activation of AMPK bymetformin is affected by raised G6P, we
compared phospho-AMPK immunoactivity in conditions of
low and highG6Pwith 25mM glucose S4048 in control hepa-
tocytes from AMPKlox/lox mice. Phosphorylation of AMPK by
high metformin (0.5 mM) and by A-769662 (10 M) was not
attenuated by high glucose S4048 compared with 5 mM glu-
cose (Fig. 3C). Hepatocytes from AMPK-KO mice had similar
levels of cell ATP in control conditions without S4048 with either
25mMglucose (Fig. 3,D andE) orwith5mMDHA(Fig. 3,F andG)
and similar elevation ofG6Pwith S4048 at 25mMglucose orDHA
(Fig. 3,H–K) as control hepatocytes from AMPKlox/lox mice. The
Metformin lowers glucose 6-phosphate in hepatocytes
J. Biol. Chem. (2020) 295(10) 3330–3346 3331
 at N
ew
castle U
niversity on M
arch 6, 2020
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
AMPK-KO hepatocytes showed small but significant lowering of
ATPwith S4048 (Fig. 3,L andM), which is best explained by com-
promised ATP homeostasis in conditions of raised G6P. Met-
formin (0.2 and 0.5 mM) caused similar or greater fractional low-
ering of G6P in AMPK-KO hepatocytes with high glucose 
S4048orwithDHAS4048 as forAMPKlox/lox controls (Fig. 3,N
andO). This indicates involvement ofAMPK-independentmech-
anisms in themetformin lowering of G6P.
Figure 1.Metformin accumulation in hepatocytes and effects on cell G6P andATP. A and B, cell metformin inmouse hepatocytes incubated inMEMwith
5 mM glucose and [14C]metformin at the concentrations indicated for 2 h followed by a further hour with added 25 mM glucose (n 4–9). Cell metformin is
expressed as nmol/mg cell protein (A) or as intracellular/extracellular concentration ratio (B). C–N, rat or mouse hepatocytes were incubated for 2 h in MEM
containing 5 mM glucose and the metformin concentrations indicated without (open bars) or with (shaded bars) S4048, followed by a further 1 h with the
substrates indicated for determination of G6P (C–I) or ATP (J–M). Cell G6P is expressed as a percentage of control without S4048 (C–E) or a percentage of
respective control with or without S4048 (F–I). ATP is expressed as nmol/mg protein. C and J, 5 mM glucose, rat hepatocytes; D and K, 25 mM glucose, rat
hepatocytes; E and L, 25mMglucose,mouse hepatocytes;H andM, 5mMglucose 5mM-DHA; I andN, 5mMglucose 2mMxylitol; F andG showdata inD and
E normalized to respective control (means  S.E. for n  3 (E, I, L, and N), 4 (C, D, J, and K), and 7 (H and M) hepatocyte preparations). *, p  0.05 effect of
metformin (C–N); #, p 0.05 effect of S4048 (C–E).
Metformin lowers glucose 6-phosphate in hepatocytes
3332 J. Biol. Chem. (2020) 295(10) 3330–3346
 at N
ew
castle U
niversity on M
arch 6, 2020
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
Rotenone, an uncoupler, and an NNT inhibitor lower G6P
To test for mechanisms linked to mitochondrial function
(Fig. 4A), we compared metformin with a complex 1 inhibitor
(rotenone), an uncoupler (dinitrophenol (DNP)), and with ber-
berine, which causes mitochondrial depolarization similar to
metformin (30). Rotenone, DNP, and berberine caused compa-
rable lowering of G6P as metformin (Fig. 4B), with negligible
effect on ATP (Fig. 4C). To test whether the metformin mech-
anism is similar to that of rotenone or the uncoupler, we deter-
mined themetabolism of [U-14C]glucose to 14CO2 as ameasure
of mitochondrial oxidation (Fig. 4D). Glucose oxidation was
inhibited by rotenone, as expected for a complex I inhibitor,
which promotes an increase in NADH/NAD ratio, and it was
stimulated with DNP, consistent with dissipation of the proton
gradient and increased electron transport.Metformin inhibited
glucose oxidation at 500 M (Fig. 4D), consistent with inhibi-
tion of complex I at this concentration (31). However, lower
metformin concentrations had no effect on glucose oxidation
(Fig. 4D). The similar lowering of G6P by rotenone and DNP,
which have opposite effects on substrate oxidation, implicates
Figure 2. Opposite effects of AMPK activators and metformin on glycolysis and gluconeogenesis in rat hepatocytes. Incubations with metformin or
AMPK activators were for 2 h followed by 1 h of incubation with substrate as in Fig. 1. A and B, phosphorylation of ACC, acetyl-CoA carboxylase–S79 by
metformin and A-769662 (A) and by the three AMPK activators: C13, C-991, and A-769662 (B). Representative blots and densitometry are shown. C–E, cell G6P
and ATP and production of lactate pyruvate with 25mM glucose. F and G, cell G6P and ATPwith 5mMDHA and 5mM glucose. H, glucose production from 5
mM DHA in glucose-free medium. I–K, Gck, G6pc, and PklrmRNA in rat hepatocytes after 4 h of incubation with the additions indicated at 5 or 45 mM glucose.
Thevalues are themeansS.E. forn4–6 (A andB), 4–10 (C–H), and4–5 (I–K). *,p0.05 relative to respective control (C–H) or relative tohighglucose control
(I–K).
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Figure 3.Metformin lowers G6P in hepatocytes fromAMPK-KOmice. A, immunoactivity to AMPK in hepatocytes fromAMPK12lox/loxmice (M1,M7, and
M8) and AMPK12lox/lox Alb-CRE (M2–M6) mice designated AMPK-KO. B, immunoactivity to AMPK-T172(P) after 3 h of incubation with metformin (0.2 or 0.5
mM) or A-769662 (10 M) in hepatocytes from AMPK12lox/lox control and AMPK-KO mice. C, immunoactivity to AMPK-T172(P) in hepatocytes from
AMPK12lox/lox incubated for 3 h with or without metformin (0.2 or 0.5 mM) or A-769667 (10 M) at either 5 or 25 mM glucose  S4048, representative
immunoblot and densitometry for n 3mice. *, p 0.05 versus respective control; #, versus respective 5mM glucose.D–O, hepatocytes from AMPKlox/lox (n
3) or AMPK-KO (n 5) mice were preincubated for 2 h with or without metformin (0.2 or 0.5 mM) or A-769662 (10 M) for 2 h followed by 1 h of incubation in
mediumwith either 25mMglucosewithorwithout S4048orwith 5mMDHAwithorwithout S4048 for determinationof cell ATP (D–G) andG6P (H–K) expressed
as nmol/mg protein. L and M, ATP from treatments with 25 mM glucose  S4048 expressed as a percentage of controls without S4048. N and O, G6P from
treatments with 25 mM glucose  S4048 expressed as percentages of control with S4048. *, p  0.05 versus respective control; #, versus substrate control
without S4048 (S). Con, control.
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Figure 4. Rotenone, dinitrophenol, and rheinmimic the G6P lowering bymetformin. A, target sites of mitochondrial inhibitors: rotenone, complex
1 (C1); DNP, uncoupler (dissipation of proton gradient); and rhein, inhibitor of NNT. B–K, incubations with metformin and mitochondrial inhibitors were
for 2 h followed by 1 h of incubation with substrate as in Fig. 1. B and C, cell G6P and ATP in rat hepatocytes incubated withmitochondrial inhibitors. The
values are means S.E. for n 3–15. D, glucose oxidation in mouse hepatocytes incubated with 15 mM [U-14C]glucose for 1 h (after 2 h with or without
metformin). The values are means S.E. for n 3. E, rhein raises cell NADP and lowers G6P (n 5 G6P,ATP; 2 NADP). F–H, effects of metformin and 2mM
NH4Cl on NADP, G6P, and ATP (n 4). I–K, metformin lowers G6P in hepatocytes from mice with either an intact (WT) or lacking a functional Nnt gene
(Nnt del; n 7–8; J and K). The values are means S.E. *, p 0.05 versus respective control (B–K); #, p 0.05, 25 mM versus 5 mM glucose (F).
Metformin lowers glucose 6-phosphate in hepatocytes
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the decrease in the mitochondrial proton gradient as a possible
link to the G6P lowering. Mechanisms linked to the mitochon-
drial proton gradient include ATP synthase (complex V) and nic-
otinamide nucleotide transhydrogenase (NNT), which generates
NADPH from NADH, NADP, and proton import (Fig. 4A). We
next tested whether rhein (4,5-dihydroxyanthraquinone 2-car-
boxylic acid), an inhibitor ofNNT (32), lowersG6P.Rhein (40M)
raised NADP, as expected (33), and lowered G6P in conditions of
maintained ATP (Fig. 4E), suggesting a possible role for either
NNT inhibition or for the raised NADP/NADPH ratio.
Metformin raises NADP but NNT deletion does not abolish the
G6P-lowering effect of metformin
To test for possible involvement of NNT activity or raised
NADP in theG6P-lowering effect ofmetformin,we determined
cell NADP in incubations with metformin, and we also tested
NH4 (2 mM), which raises NADP by consumption of NADPH
during urea synthesis (33, 34). Cell NADP was higher at 5 mM
glucose than at 25 mM glucose and was raised by NH4 at low
and high glucose and by 500Mmetformin at high glucose (Fig.
4F). NH4, like metformin, lowered G6P at high glucose (Fig.
3G) with no effect on ATP (Fig. 4H). The raised NADP by met-
formin and the lowering of G6P by rhein and NH4, which raise
NADP by different mechanisms (33, 34), support potential
roles for compromised NNT activity or for the raised NADP/
NADPH in the G6P lowering, for example by increased activity
of the pentose pathway, which uses G6P and NADP as sub-
strates. To test for a role of NNT we determined the effects of
metformin in hepatocytes frommice with a deletion in theNnt
gene (35) (Fig. 4I). The lowering of G6P bymetformin was sim-
ilar in hepatocytes without or with a functionalNnt gene (Fig. 4,
J and K). This indicates involvement of mechanisms other than
NNT inhibition in the G6P depletion by metformin.
Changes in glucose phosphorylation or glycogenmetabolism
cannot explain themetformin lowering of G6P
We tested which candidate metabolic pathways are involved
in the metformin mechanism (Fig. 5A). Depletion of G6P may
result from inhibition of G6P generating pathways (e.g. glucose
phosphorylation, gluconeogenesis, or glycogenolysis) or stimu-
lation of G6P-consuming pathways (glycogen synthesis, glycol-
ysis, or pentose pathway). We used [2-3H]glucose to measure
glucose phosphorylation and [3-3H]glucose to determine G6P
metabolism by glycolysis and the pentose pathway. Glucose
phosphorylationwasmodestly inhibited byA-769662 andC-13
and by 2.5 mM metformin but not by lower metformin (0.2–1
mM) (Fig. 5, B and C). Similarly glucokinase translocation by
high glucose was inhibited by 2.5–5 mM metformin but not by
0.5 mMmetformin (Fig. 5D). Detritiation of [3-3H]glucose (Fig.
5C, shaded bars) relative to [2-3H]glucose was increased by
metformin (0.2–1 mM), indicating stimulation of glycolysis
and/or pentose pathway after G6P formation.
In the presence of a glucokinase activator (GKA) to maxi-
mally activate endogenous glucokinase, low metformin also
modestly increased [3-3H]glucose metabolism (Fig. 5E) and
formation of lactate and pyruvate (Fig. 5F), whereas in the pres-
ence of mannoheptulose, a glucokinase inhibitor, the effects of
metformin on pyruvate and lactate formation (Fig. 5F) and on
G6P (Fig. 5G) were abolished. Cumulatively, this implicates
metformin stimulation of G6P disposal by glycolysis and/or the
pentose pathway downstream of glucose phosphorylation at
endogenous or raised but not attenuated glucokinase activity.
Lowering of G6P can occur in conditions of stimulation of gly-
cogen synthesis (36).We therefore tested the effects ofmetformin
onglycogen synthesis (Fig. 5H).Metformin caused concentration-
dependent inhibition of glycogen synthesis (Fig. 5H), and this cor-
relatedwith theG6P lowering (r 0.99; Fig. 5, I and J).Metformin
also inhibited glycogen storage with 25 mM glucose and DHA as
substrates (Fig. 5K). G6P is amajor regulator of glycogen synthesis
(37). These results rule out a role for changes in glycogenmetabo-
lismas a cause ofG6Pdepletion but implicate theG6P lowering as
the cause of the impaired glycogen synthesis.
Flux through glycolysis and the pentose pathway determined
with [1,2-13C2]glucose: converse effects of metformin and
AMPK activators
To test whether metformin increases flux through the pen-
tose pathway, we first used [1-14C]glucose and [6-14C]glucose
to estimate flux from the difference in 14CO2 formation ([1-
14C] minus [6-14C]glucose). However, decarboxylation of
[1-14C]glucose was lower than from [6-14C]glucose. This was
not due to impurities in the [1-14C]glucose but to lack of equil-
ibration at the triose phosphate isomerase step (38). This was
confirmed from incubation with ethanol (39), which inhibited
14CO2 formation from [6-14C]glucose but not [1-14C]glucose
(results not shown).
We next used [1,2-13C2]glucose to measure partitioning of
flux between glycolysis (via PFK1) and the pentose pathway (via
glucose 6-phosphate dehydrogenase) from [13C]lactate mass
isotopologs: m0, m1, and m2, where m0 represents unlabeled
lactate, and m1 and m2 represent lactate with one or two 13C
atoms, respectively (Fig. 6A). Metabolism of [1,2-13C2]glucose
by the pentose pathway generates m1 and m0 lactate, whereas
glycolysis generates m2 and m0 lactate. Pyruvate cycling in
mitochondria would lead to conversion of m2 to m1. Incuba-
tions were performed with -cyano-4-hydroxycinnamate and
amino-oxyacetate to inhibit substrate entry into mitochondria
as pyruvate or alanine (40) in medium without glutamine. We
confirmed inhibition of entry of glucose carbon intomitochon-
dria from the lack of 13C incorporation into glutamate. The
medium also contained S4048 to prevent flux through glucose
6-phosphatase. Comparison of glucose isotopologs at the start
and end of the incubation confirmed no change in 13C distribu-
tion inmedium glucose. In these conditions the ratio of m2/m1
lactate is ameasure of the relative G6P flux by glycolysis (PFK1)
versus pentose pathway (Fig. 6A). Metformin (100–500 M)
had two effects on [13C]lactate mass isotopolog distribution. It
increased the fraction of lactate derived from glucose (Fig. 6B),
and it increased them2/m1 ratio (Fig. 6C). TheAMPKactivator
decreased the m2/m1 ratio (Fig. 6C). Cumulatively metformin
stimulates glycolysis via PFK1 in absolute terms and relative to
flux via the pentose pathway, whereas the AMPK activator had
the converse effect on the m2/m1 ratio. NH4 (2 mM)
increased the fraction of lactate derived from glucose with-
out changing the m2/m1 ratio, indicating increased glycoly-
sis and possibly also pentose pathway.
Metformin lowers glucose 6-phosphate in hepatocytes
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Modulation of cell G6P by inhibition of PFK-1 or FBP1 activity
To identify candidate mechanisms for the G6P lowering, we
determined the effects of targeted inhibition of PFK1or FBP1.We
first expressed a kinase-deficient variant of the liver isoform
(PFKFB1) of 6-phosphofructo-2-kinase/fructose-2,6-bisphospha-
tase (PFK2-KD), which functions as a constitutively active bispho-
sphatase and depletes fructose-2,6-P2 (14), an activator of PFK1
and inhibitor of FBP1 (41). PFK2-KD causedmodest (20%) low-
ering of pyruvate lactate formation (Fig. 7A) but raised G6P by
3-fold (Fig. 7B).Wenextused thecitrateanalogaurintricarboxy-
lic acid (ATA),which is apotent inhibitorofPFK1andantagonizes
activation by fructose-2,6-P2 (42). ATA caused concentration-de-
pendent lowering of pyruvate and lactate formation and increased
G6P by 3-fold also at the lowest concentrations tested (Fig. 7C).
The lowest [ATA] tested (50 M) lowered metabolism of both
[2-3H]glucose and [3-3H]glucose by 233%and322%, respec-
Figure 5.G6P loweringbymetformin is not explainedby inhibitionof glucosephosphorylationor stimulationof glycogen storage.A, loweringofG6P
canoccur by inhibition of G6Pproducingor stimulation of G6P-consumingpathways. B–K, incubationswithmetformin and activators or inhibitorswere for 2 h
followed by 1 h of incubation with substrate and radiolabel. B, metabolism of [2-3H]glucose in rat hepatocytes (n 7), except 2.5 mM metformin (n 2). C,
metabolism of [2-3H]glucose and [3-3H]glucose inmouse hepatocytes (n 4–5).D, glucokinase translocation 25mM versus 5mM glucose (n 20–30 fields in
2–3 rat hepatocyte preparations) and representative images above. Scale bars, 10m. E–G, mouse hepatocytes: effects of metformin (0.2mM) in combination
with a GKA (10M Ro-20-1675) ormannoheptulose (MH, 10mM) onmetabolism of [2-3H],[3-3H]glucose (E), lactate and pyruvate (F), and cell G6P (G) (n 3–9).
H–J, glycogen synthesis and cell G6P: concentration-dependent inhibition of glycogen synthesis bymetformin and correlationwith G6P (n 3). K, metformin
inhibits glycogen storagewith high glucose or DHA (n 3). *, p 0.05 effect ofmetformin or AMPK activator; #, p 0.05 [3-3H]glucose versus [2-3H]glucose (C)
or 25 mM glucose versus 5 mM glucose (D).
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tively (Fig. 7D), with greater (p  0.05) fractional inhibition of
[3-3H]glucose, consistentwith inactivationofPFK1(42).An inhib-
itorofFBP1causedconcentration-dependent loweringofG6Pbut
without increasing lactate and pyruvate production andwithATP
lowering (Fig. 7E). Treatment with amino-oxyacetate (AOA), an
inhibitor of the aspartate shuttle, to inhibit transfer of NADH
equivalents tomitochondria and thereby increase the cytoplasmic
NADH/NAD (43) as shown by the increase in lactate/pyruvate
ratio (Fig. 7F) had no effect on cell G6P (Fig. 7G). This establishes
that selective targeting of PFK1 and/or FBP1 but not targeting
downstream glycolysis with an increase in cytoplasmic NADH/
NAD redox state affects G6P levels.
Candidate effectors of PFK1-increased Pi
The 3-fold increase in G6P with the PFK1 inhibitor (42)
despite modest inhibition of pyruvate and lactate formation
(Fig. 7,C andD) suggests that allosteric effectors of PFK1 could
account for the G6P lowering by metformin with concomitant
increased glycolysis (Figs. 2E; 5, C, E, and F; 6; and 7A). Candi-
date PFK1 activators include AMP, Pi, NH4, fructose 2,6-P2,
and fructose 1,6-P2, and inhibitors include citrate andG3P (41).
Fructose 2,6-P2 is lowered by metformin (18) and therefore
cannot explain the increased glycolysis. Pi is a candidate effec-
tor because mitochondrial [Pi] is severalfold higher than cyto-
plasmic Pi, and uptake into mitochondria is by electrogenic
transport (44). Accordingly mitochondrial depolarization by
lowmetformin (45) would be expected to increase cytoplasmic
Pi. Total cell Pi was increased by highDNP (100M) as expected
(46) and by high (500M)metformin (Fig. 7H). An increase in
cytoplasmic Pi with negligible change in total cell Pi would be
expected at lowermetformin or DNPwithmoremodest effects
on the mitochondrial proton gradient.
Roles of G3P andmGPDH activity inmodulating cell G6P and
G6pc expression
We showed previously (31) that metformin lowers G3P, a
substrate for mGPDH and cGPDH and an inhibitor for PFK-1
(41), in conditions of gluconeogenic flux andproposed a role for
the lowerG3P in activation of PFK1 and inhibition of gluconeo-
genesis (31). Liver G3P represents the balance between forma-
tion from exogenous glycerol (via glycerokinase) and metabo-
lism by cGPDH and mGPDH. Whereas cGPDH is present at
high activity and catalyzes the reversible interconversion of
DHAP and G3P, mGPDH is present in low activity in liver and
catalyzes the irreversible oxidation of G3P to DHAP (47). We
tested the hypothesis that selective lowering ofG3PbymGPDH
overexpression lowers G6P. Cells overexpressing mGPDH had
lower G3P with 25 mM glucose, DHA, and glycerol as substrate
(Fig. 8A) as expected (31), and they also had markedly lower
G6P (Fig. 8B). Interestingly, overexpression of mGPDH atten-
uated the induction of G6pc and Txnip mRNA by 25 mM glu-
cose, similarly to metformin (Fig. 8C).
TheGpd2 gene encoding mGPDHwas identified as a poten-
tial target for ChREBP in mouse liver (48). We tested whether
Gpd2 is induced by raised G6P or G3P. Hepatocytes were incu-
bated with either 25 mM glucose with or without S4048 to raise
Figure 6. Metformin but not AMPK activators stimulates glycolysis. A, metabolism of [1,2-13C2]glucose by glycolysis (to m2, m0 lactate) and pentose
pathway (m1, m0 lactate). B and C, rat hepatocytes were incubated for 1 h in MEM with 2 M S4048, 0.4 mM -cyanocinnamate, 0.5 mM AOA, and [1,2-
13C2]glucose (15mM) for determination of lactatem0, m1, andm2mass isotopologs. Metformin and A-769662 were present during the final 1 h of incubation
and during a 2-h preincubation. NH4Cl (2mM) was present during the final 1 h of incubation. The values aremeans S.E. for n 4 hepatocyte preparations. *,
p 0.05 relative to control.
Metformin lowers glucose 6-phosphate in hepatocytes
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G6P or with the reduced substrate xylitol and without or with
AOA to inhibit transfer of NADH equivalents from the cyto-
plasm and further raise G3P. The highest G6P elevation was
with high glucose  S4048 (Fig. 8D), and the highest G3P was
with xylitol  AOA (Fig. 8E). Expression of ChREBP-
was raised by 30% by high glucose  S4048 (Fig. 8F), whereas
ChREBP- (Fig. 8G), which is a sensitive marker of ChREBP
activation (49), was increased by 5- and 4-fold, respectively, by
high G6P (25 mM glucose with S4048) and by high G3P
(xylitolAOA) andwas also significantly induced bymoderate
elevation in G6P and G3P with high glucose or xylitol without
inhibitors but not with AOA alone. This indicates activation of
ChREBP- by triose-P (G3P), as well as hexose-P (G6P). G6pc
mRNAwas induced to a greater extent by raisedG6P compared
with raised G3P (Fig. 8H), 10-fold versus 3-fold (p  0.05),
whereas Gpd2 mRNA was induced similarly (Fig. 8I) by
raised G3P (61% by xylitol  AOA) and by G6P (74% by
25G  S4048). This shows that the Gpd2 gene is induced
by raised G6P and by G3P (Fig. 8, D, E, and I) and that raised
mGPDH activity attenuates the raised G3P and G6P by sub-
strate challenge (Fig. 8, A and B) and similarly to metformin
it attenuates G6pc induction by high glucose (Fig. 8C). This
supports a role for the lower G6P and G3P in the metformin
repression of G6pc.
Dinitrophenol and rotenonemimic the G3P lowering by
metformin
Wenext explored themechanisms for G3P lowering bymet-
formin. In liver cells in the absence of exogenous glycerol,
changes in cell G3P result mainly from changes in the cytoplas-
mic NADH/NAD redox state via the cGPDH equilibrium (Fig.
9A) or from changes in mGPDH activity, which transfers the
electrons fromG3P oxidation to themitochondrial ubiquinone
pool (Fig. 9A). Cell G3P was moderately raised by elevated glu-
cose (15–25 mM) and by 5 mM DHA and was further raised by
AOA, whereas ATP was unchanged (Fig. 9, B and C). The
Figure 7. Changes in hepatocyte G6P during selective targeting of PFK1 and/or FBP1. A and B, mouse hepatocytes were either untreated or treatedwith
an adenoviral vector (PFK-KD) to deplete fructose 2,6-P2 and after overnight culture were incubated for 2 hwith S4048 andwithout or with 0.2mMmetformin
and for a further 1 hwith 25mMglucose. A, lactate pyruvate production. B, cell G6P (n 7–10). C andD, mouse hepatocytes were incubatedwith S4048 and
the concentrations of ATA indicated for 2 h and then for 1 h with 25 mM glucose. C, cell G6P and ATP and lactate pyruvate. D, metabolism of [2-3H]glucose
and [3-3H]glucose. E, incubations were as for C but with the FBP1 inhibitor (FBPi) concentrations as indicated. F and G, mouse hepatocytes were incubated for
2 hwithout orwith 200Mmetformin and then for a further 1 hwith 25mMglucosewithout orwith 100MAOA (n 5–6).H, cell Pi inmouse hepatocytes (n
3) after 2 h of incubation with metformin and inhibitors and for a further 1 h with 25 mM glucose.*, p 0.05 effect of metformin or inhibitor; #, p 0.05 effect
of PFK-KD.
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increase byAOA is explained by the raised cytoplasmicNADH/
NAD ratio (43) as shown by the raised lactate/pyruvate ratio
(Fig. 7F), which increases conversion of DHAP to G3P by
cGPDH (Fig. 9A). The uncoupler DNP, which stimulates mito-
chondrial pyruvate oxidation by dissipation of the mitochon-
drial proton gradient, mimicked metformin and lowered G3P,
with both DHA (Fig. 9, D and E) and 25 mM glucose (Fig. 9, F
and G) irrespective of the presence of AOA, with no change in
ATP.TheDNPeffect onG3P is consistentwith amore oxidized
ubiquinone redox state, by dissipation of the proton gradient.
Rotenone (0.25–1 M), an inhibitor of complex 1, caused con-
centration-dependent lowering of G3P in the presence of AOA
andmoremodest lowering of G3P at0.5M in the absence of
AOA (Fig. 9H) with mild lowering of ATP at 1 M rotenone
(Fig. 9I). In the absence of AOA low rotenone (0.25 M) raised
lactate plus pyruvate production and the lactate/pyruvate ratio
(Fig. 9, J and K), indicating a raised cytoplasmic NADH/NAD.
The latter predicts G3P elevation via cGPDH. Accordingly,
rotenone has opposite effect on G3P via cGPDH and mGPDH.
In the presence of ethanol, whichmarkedly raised cell G3P (Fig.
9, L–O), as expected (50), the fractional lowering of G3P by
DNP was increased from 40–70% to 70–85% (Fig. 9L versus
9F), and the lowering of G3P by rotenone was also increased
(Fig. 9, N versus H). Metformin (100–200 M) modestly low-
ered G3P in all conditions tested (Fig. 9, D, F, L, and N).
Because metformin raises the lactate/pyruvate ratio (Fig.
7F), the metformin effect on G3P cannot be explained by the
cytoplasmic NADH/NAD redox state and therefore indi-
cates increased mGPDH activity. Cumulatively, G3P lower-
ing by DNP, rotenone, and metformin is best explained by a
more oxidized mitochondrial ubiquinone redox state.
Figure8.OverexpressionofmGPDHlowersG6Pandmimics themetformin repressionofG6pc.A–C, after cell attachmentmousehepatocyteswereeither
untreated or treated (4 h) with an adenoviral vector (Ad-m-Gpd2 at 4.8  107 plaque-forming units/ml) for overexpression of mGPDH (mGPDH-OE). After
overnight culture, the hepatocytes were incubated for 2 h in MEM without or with 100 M metformin (as indicated). A and B, the medium was then supple-
mented with 25 mM glucose (25G), 5 mM DHA, or 2 mM glycerol, and incubations were for a further 1 h for determination of cell G3P and G6P. C, the substrate
was 25mMglucosewith additional controls at 5mMglucose, and incubationswere for a further 4 h for RNAextraction andmRNAanalysis, whichwas expressed
relative to 5mM glucose control (1.0). The values are means S.E. (n 3–5). *, p 0.05 relative to untreated. D–I, after overnight culture, mouse hepatocytes
were incubated with either 25mM glucose (25G) without or with S4048 (25GS) or with 2mM xylitol (Xyl) or 0.2 mM AOA alone or in combination. Incubations
were either for 60 min for determination of cell G6P and G3P (D and E) or for 4 h (F–I) for RNA extraction and analysis of ChREBP- (F), ChREBP- (G), G6pc (H),
and Gpd2 (I) mRNA, which is expressed relative to respective control at 5 mM glucose. The values are means S.E. (n 4–5 (D and E) or n 6–7 (G–I)). *, p
0.05 versus control.
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Discussion
We show in this study that metformin lowers G6P in hepa-
tocytes challenged with gluconeogenic precursors or high glu-
cose by increased flux through glycolysis, downstream of G6P
and not through effects on glucose phosphorylation or glyco-
gen metabolism. This G6P lowering manifests over a wide
range of cell metformin concentrations from the therapeutic
range (1–2 nmol/mg cell protein) to 10-fold higher and is not
Figure 9. Effects of amino-oxyacetate and mitochondrial inhibitors on hepatocyte G3P and ATP in mouse hepatocytes. A, cell G3P represents the
balance between formation from exogenous glycerol; cGPDH, which catalyzes the reversible NADH/NAD-dependent interconversion of DHAP and G3P; and
mGPDH, which catalyzes the irreversible oxidation of G3P to DHAP with transfer of electrons to mitochondrial ubiquinone (Q). Rotenone inhibits the transfer
of electrons fromcomplex1 (C1) toubiquinone.B–O, hepatocyteswere incubated for 1h inMEMwith the substrates indicatedwithout (openbars) orwith (filled
bars) 200 M amino-oxyacetate for analysis of cell G3P and ATP (nmol/mg protein). In J and K, lactate and pyruvate were determined in the medium of the
60-min incubation. The glucose (G) concentration was 5 mM unless otherwise indicated, and ethanol (L–O) was 15 mM. Metformin (100 or 200 M), where
indicated (D–G and L–O), was present in a 2-h preincubation and during the final 1-h incubation. Concentrations of rotenone (Rot), DNP, andmetformin (Met)
are shown inM. The values aremeans S.E. (n 4 (B, C, F, andG), n 6 (D and E), and n 2 (H–O) hepatocyte preparations eachwith triplicate incubations).
*, p 0.05 relative to respective control; #, p 0.05 effect of AOA.
Metformin lowers glucose 6-phosphate in hepatocytes
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mediated by AMPK-dependent mechanisms. It is a candidate
mechanism for the repression of G6pc by low metformin in
animal models of diabetes (12, 13) and in hepatocytes from
AMPK-deficient mice (10).
The induction ofG6pc (encoding glucose 6-phosphatase) by
high glucose is linked to raised metabolites of glucose rather
than to glucose itself via activation of the transcription factor
ChREBP, which binds to the liver G6pc gene promoter (14, 15)
and is explained by the adaptive role of glucose 6-phosphatase
in maintaining cellular homeostasis of ATP and hexose phos-
phates (16, 17).We show thatGpd2 (encodingmGPDH), which
is a candidate target gene of ChREBP (48), is induced by raised
phosphate esters in conditions of ChREBP- induction. This
indicates an analogous role for mGPDH as for glucose 6-phos-
phatase (G6pc) in cell phosphate ester homeostasis in condi-
tions of glucose excess. We also show that overexpression of
mGPDHattenuates the elevation in both hexose phosphate and
triose phosphate and mimics the G6pc repression by met-
formin, thus supporting a role for lowering of phosphometabo-
lites in the metformin mechanism on G6pc.
The metformin efficacy in G6P lowering manifests in condi-
tions of raised intracellular metabolites, as occurs with high
glucose or gluconeogenic precursors, and is further enhanced
by theG6P transport inhibitor (S4048), which further enhances
G6P elevation (24–26). The finding that the lowering of G6P by
metformin was abolished with a glucokinase inhibitor, which
lowers G6P is of interest because metformin is known to be
ineffective in maturity-onset diabetes of the young linked to
inactivating mutations in the GCK gene (51). This further sup-
ports a role for the G6P lowering in the therapeutic effect of
metformin in type 2 diabetes (2).
In the liver, several metabolic pathways can contribute to the
G6P lowering bymetformin. G6P is generated by glucose phos-
phorylation, glycogen degradation, and gluconeogenesis and
metabolized by glycogen synthesis, glycolysis, pentose pathway,
and other minor pathways.We can firmly exclude inhibition of
glucose phosphorylation because only very high metformin
(1mM) inhibited glucose phosphorylation in association with
ATP depletion.We also excludemetformin effects on glycogen
metabolism (synthesis or degradation) as a cause of the G6P
lowering because metformin decreased rather than increased
glycogen synthesis and storage, at all concentrations tested, in
agreement with previous findings (52). G6P is a key activator of
glycogen synthase (37) and inhibitor of glycogen phosphorylase
(53). Accordingly, the correlation between G6P lowering and
inhibition of glycogen synthesis with increasing metformin
points to the decline in G6P as the primary mechanism with
attenuation of glycogen synthesis, as secondary to G6P deple-
tion, through partitioning toward glycolysis. The pentose path-
way usesG6P as substrate and generatesNADPH. Flux through
this pathway is determined by the NADP/NADPH ratio (54)
and is increased when other pathways for NADPH production
(such as NNT, which is driven by the mitochondrial proton
gradient) are compromised or when there is increased con-
sumption of NADPH, for example by urea synthesis (34). We
considered this pathway as a potential mechanism because
metformin raised NADP, and in addition, an NNT inhibitor
and ammonium ion, which raise NADP by different mecha-
nisms, both lowered G6P. However, the data onNNT-deficient
hepatocytes indicate a mechanism independent of NNT, and
furthermore the depletion of G6P by NH4 can be explained by
allosteric activation of PFK1 (41).
A role for activation of glycolysis at PFK1by lowmetformin is
supported by various sets of evidence. First, metabolism of
[2-3H]glucose and [3-3H]glucose, which measure respectively,
glucose phosphorylation and downstream G6P metabolism by
glycolysis and/or pentose pathway showed higher stimulation
by metformin of detritiation of [3-3H]glucose compared with
[2-3H]glucose. Second, lactate isotopomers (m2/m1 ratio) from
[1,2-13C]glucose revealed both a relative increase in glycolysis
versus pentose pathway and an absolute increase in glycolysis.
Third, the citrate analog (ATA) which is a potent inhibitor of
PFK1 (42) caused 3-fold elevation in G6P despite modest inhi-
bition of glycolysis, whereas targeting downstream glycolysis
with amore reduced cytoplasmic NADH/NAD redox state had
negligible effect on G6P. This cumulatively supports a role for
allosteric regulation at a proximal site of glycolysis after hexose
6-P formation by targeting of PFK1 and/or FBP1.
FBP1 is inhibited by fructose-2,6-P2 andAMP,whereas PFK1
is inhibited by citrate and G3P and activated by fructose 2,6-P2,
AMP, Pi, NH4, and other effectors (41). Fructose 2,6-P2, which
has amajor role in hepatic regulation of glycolysis by hormones
and high glucose, can be excluded from the metformin mecha-
nism on glycolysis and G6P because it is lowered by metformin
(18). A somewhat analogous mechanism occurs in hepatocytes
during anoxia, which promotes glycolysis with concomitant
lowering of fructose 2,6-P2 (55) but with raised AMP and low-
ered citrate, which stimulate and inhibit PFK1, respectively (41,
55). Candidate allosteric effectors to explain the stimulation of
glycolysis by metformin include: raised AMP and cytoplasmic
Pi and lowered citrate and G3P. A role for raised AMP in the
inhibition of gluconeogenesis by metformin was recently dem-
onstrated using a knockinmousemodel for anAMP-insensitive
variant of FBP1 (56). Metformin has been shown to lower cit-
rate levels in a metabolomics study on the Zucker diabetic fatty
rat (57) and to lower G3P in hepatocytes incubated with gluco-
neogenic precursors (31, 58). The lowering of G3P by met-
formin contrasts with the marked elevation during anoxia (55)
and is best explained by mitochondrial depolarization, which
favors increased flux through mGPDH.
Cytoplasmic G3P levels are determined by the cGDH equi-
librium through changes in the NADH/NAD redox and by the
activity of mGPDH, which oxidizes cytoplasmic G3P by trans-
fer of electrons to ubiquinone in the electron transport chain.
mGPDH has low affinity for its substrate G3P (47) and thereby
a minor role on cell G3P at low substrate when changes in cell
G3P would predominantly reflect changes in the cytoplasmic
NADH/NAD redox state through the cGDH equilibrium. Here
we used high substrate or ethanol to raise G3P. Lowering of
G3P by rotenone and metformin in conjunction with an
increase in the lactate/pyruvate ratio, which implicates an
increase in theG3P/DHAPvia the cGDHequilibrium, indicates
increased flux through mGPDH. The studies with the uncou-
pler support a role formitochondrial depolarization in lowering
G3P and G6P and also raising cell Pi (an activator of PFK1).
Cumulatively this supports multiple allosteric effectors includ-
Metformin lowers glucose 6-phosphate in hepatocytes
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ing lowerG3P and citrate (57) and raised Pi andAMP (56) in the
metformin activation of PFK1. It does not exclude a role for the
raised AMP causing inhibition of FBP1 as shown recently with
a knockin mouse model for an AMP-insensitive FBP1 variant
(56).
Two widely studied mechanisms of metformin are the inhi-
bition of complex 1 (19, 59–63) and the activation ofAMPK (63,
64). The latter can occur either by a “canonical” pathway down-
stream of inhibition of complex 1 and consequent mitochon-
drial depolarization resulting in compromised phosphorylation
potential and thereby raised AMP or by a “noncanonical” path-
way linked to sensing of fructose 1,6-P2 (65, 66). Arguments in
support of involvement of complex 1 in activation of AMPK by
the canonical pathway have been reviewed (63). The nonca-
nonical pathway occurs in conditions of depletion of fructose
1,6-P2, which promotes formation of an AMPK multiprotein
complex at the lysosome comprising AXIN, LKB1, Ragulator,
v-ATPase, and aldolase functioning as the fructose 1,6-P2 sen-
sor (65, 66). We can exclude a role for AMPK activation in the
G6P-lowering mechanism because metformin was equally
effective in AMPK-KO hepatocytes. However, we cannot
exclude involvement of other stress kinases like PKD andMK2
that may be activated through LKB1-independent mechanisms
at high metformin (67). In this study, high substrate challenge
showed trends of lower AMPK phosphorylation basally and
with low metformin (0.2 mM) but enhanced AMPK phosphor-
ylation with high metformin (0.5 mM), indicating that raised
hexose phosphates do not antagonize AMPK activation by the
canonical pathway.
A key outstanding and contentious issue is whether inhibi-
tion of complex 1 is involved the therapeutic effects of met-
formin (63, 64). Inhibition of the oxygen consumption rate (19,
59) or glucose (pyruvate) oxidation by highmetformin are con-
sistent with inhibition of complex 1 andmimicked by rotenone.
In this studywe found inhibition of glucose oxidation by 0.5mM
but not by 0.2 mM metformin, and this concurs with studies
showing inhibition of oxygen consumption at  0.3 mM met-
formin (68). Although high metformin (0.5 mM) promotes a
more reduced mitochondrial NADH/NAD ratio, consistent
with complex 1 inhibition (31), low metformin (0.2 mM) pro-
motes a more oxidized NADH/NAD ratio and increased -oc-
tanoate oxidation, implicating increased electron transport
(31). Nonetheless, glucose (pyruvate) oxidation was unchanged
at low metformin (0.2 mM). We cannot exclude a role for tar-
geting of complex 1 by low metformin, whereby metformin
causes uncoupling of proton pumping as proposed byCameron
et al. (62), and the consequent mitochondrial depolarization
favors increased electron transport and increased flux through
mGPDH. Depolarization of mitochondria by low metformin
has been reported (45).Whethermechanisms independently of
complex 1 can explain such a depolarization remains specula-
tive (31). Cumulatively, this study shows that the lowering of
G6P in conditions of substrate challenge by metformin is mim-
icked by mitochondrial depolarization with an uncoupler or by
a complex 1 inhibitor and that multiple allosteric effectors of
PFK1, including lower G3P and raised Pi, as well as raised AMP
(56) and lower citrate (57), can contribute to the increased dis-
posal of G6P by glycolysis.
Experimental procedures
Reagents
A-769662 was from Tocris Biosciences; the AMPK activator
C-13 was from the Division of Signal Transduction Therapy,
University of Dundee; compound 991 was synthesized by
SpiroChem (69); the GKA Ro28-1675 was from Axon Med-
Chem BV (Groningen, The Netherlands); the FBP1 inhibitor
5-chloro-2-[N-(2,5-dichlorobenzenesulfonamide)]-benzo-
xazole (14) was from Calbiochem/Santa Cruz; and S4048
(1-[2-(4-chloro-phenyl)-cyclopropylmethoxy]-3,4-dihy-
droxy-5-(3-imidazo[4,5-b]pyridin-1-yl-3-phenyl-acryloy-
loxy)-cyclohexanecarboxylic acid) was a kind gift from Sanofi–
Aventis. All other reagents were from Sigma or Tocris
Biosciences.
Hepatocyte isolation and culture
The mice were housed in environmental conditions as out-
lined in the Home Office Code of Practice. All animal proce-
dures conformed to Home Office Regulations and were
approved by the Animal Welfare Ethics Review Board of the
Newcastle University Ethics Committee. Hepatocytes were iso-
lated from adult male Wistar rats (Envigo, Bicester, UK) and
adult male mice, by collagenase perfusion of the liver (31).
Unless otherwise indicated, the mice were of the C57BL/6JO-
laHSD strain (Envigo). For the experiments in Fig. 3 on liver
AMPK-deficient mice, these were generated by crossing
AMPK1lox/lox,2lox/lox mice (control) against Alfp-Cre (albu-
min promoter with -fetoprotein enhancer) to generate
AMPK1lox/lox,2lox/lox–Alfp-Cre (AMPK-KO)mice, as previ-
ously described (69). For experiments on Nnt-deficient mice,
the strain was C57BL/6J (35) fromCharles River. For the exper-
iments in Fig. 9, the mice were heterozygous for P446L substi-
tution in the Gckr gene (70). The hepatocytes were suspended
inminimum essential medium (MEM) containing 5% (v/v) new
born calf serum and seeded on gelatin-coated (0.1%) multiwell
plates, glass coverslips for immunostaining (18), or glass flasks
for 14CO2 entrapment. After cell attachment the medium was
replaced by serum-free MEM containing 5 mM glucose, 10 nM
dexamethasone, and 1 nM insulin, and the experiments were
started after 20 h of culture. For experiments involving
enzyme overexpression, the hepatocytes were incubated with
adenoviral vectors for 4 h after cell attachment. For overex-
pression of mouse mGPDH, the adenoviral vector (Ad-m-
Gpd2, ADV-279685, 5  107 plaque-forming units/ml) was
generated by Vector Biolabs (Malvern, PA). The vector for
expression of a kinase-deficient bisphosphatase active vari-
ant (S32D/T55V) of 6-phosphofructo-2-kinase-fructose-
2,6-bisphosphatase, PFKFB1 (denoted by PFK-KD), was
described in Ref. 14.
Hepatocyte incubations
After overnight culture hepatocytes were preincubated for
2 h inMEMcontaining 5mM glucose and the concentrations of
metformin and AMPK activators or enzyme inhibitors as indi-
cated. The medium was then supplemented with glucose or
gluconeogenic substrates and other additions as indicated or
replaced by fresh medium with the additions including met-
Metformin lowers glucose 6-phosphate in hepatocytes
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formin at the same concentration as for the 2-h preincubation
and incubations were continued for 1 h. Where indicated,
S4048 (G6P transport inhibitor) was used to raise cell G6P at a
concentration of 0.2–2 M.
Accumulation of [14C]metforminwas as described in Ref. 18,
and metabolism of [U-14C]glucose to glycogen and [2-3H],[3-
3H]glucose to 3H2O were as described in Ref. 71. For [U-14C]
glucose oxidation, the cells were cultured in glass flasks, and for
the final incubation with [U-14C]glucose, the flasks contained a
2-ml tube and were sealed with rubber stoppers. The incuba-
tionwas terminated by injection ofHCl (0.2 M final) to the flask,
and Hyamine 10 hydroxide (300 l; PerkinElmer) was
injected into the 2-ml tube to trap the 14CO2 released by acid-
ification of the medium. For determination of cell metabolites
other than Pi, the medium was aspirated on termination of the
incubations, and the hepatocyte monolayers in multiwell pates
were snap-frozen in liquid nitrogen and stored at	80 °C until
analysis. For determination of cell ATP,G6P andG3P cellswere
extracted in 2.5% (w/v) sulfosalicylic acid and deproteinized,
and ATP was determined by chemiluminescence and G3P and
G6P fluorometrically (excitation, 530 nm; emission, 590 nm) as
in Ref. 31. For NADP assay, the cells were extracted in 0.6 M
HClO4, and after deproteinization and neutralization (3 M
KOH/1MK2HPO4), NADPwas assayed fluorometrically (exci-
tation, 340; emission, 450) with yeast glucose 6-phosphate de-
hydrogenase. For determination of Pi on termination of the
incubations, the hepatocyte monolayers were rapidly washed
two times with 300 mM sucrose, 3 mM HEPES, pH 7.4, and
extracted in 0.6 M perchloric acid (4 °C). The extracts were cen-
trifuged (9000  g, 10 min, 4 °C) and assayed immediately as
described in Ref. 72. Pyruvate and lactate in the medium were
determined by either absorbance (A340 nm) or fluorometrically
(excitation, 340 nm; emission, 450 nm) using lactate dehydro-
genase as previously described (31).
Flux analysis from [1,2-13C2]glucose
Hepatocytes were incubated in MEM without glutamine,
containing 15 mM glucose with [1,2-13C2]glucose (50%), 2 M
S4048, 0.4 mM -cyanocinnamate, 500 M aminooxyacetate,
and other additions as indicated for 1 h. The medium was col-
lected at the start and end of the incubation and derivatized for
CG-MS analysis of lactate, glucose, and glutamate, as described
in Ref. 73. The results of lactate mass isotopologs are expressed
as fractional enrichment or m2/m1 ratio (73).
Immunostaining and immunoblotting
Immunostaining for glucokinase in hepatocyte monolayers
on glass coverslips was with a rabbit GK antibody (H-88,
sc7908) as in Ref. 74. For immunoblotting, the hepatocytes
were extracted in buffer containing 100mMKCl, 10mM EDTA,
20 mM K2HPO4, 0.1% Triton X-100, 0.5 mM phenylmethylsul-
fonyl fluoride, 0.5 mM benzamidine, 1 mM DTT, 1 g/ml caly-
culin A, and 0.1% protease inhibitormixture. Samples (20g of
protein) were resolved by SDS-PAGE (90 V for 15 min and 180
V for 45 min) and transferred onto PVDF membrane (Trans
Blot SD semidry; 15 V for 45 min). The membranes were
probed for AMPK and phospho-AMPK–Thr-172 (New
England Biolabs catalog nos. 2532 and 2531), acetyl-CoA car-
boxylase–S79(P) (New England Biolabs catalog no. 3661), and
Gapdh (Hytest catalog no. ABIN153387), and protein bands
were visualized by enhanced chemiluminescence (Pierce) and
exposure to medical film (Agfa Healthcare). Densitometry was
imaged by Bio-Rad GS-800 software.
mRNA analysis
RNA was extracted from the hepatocyte monolayers with
TRIzol (Invitrogen), and cDNA was synthesized from 1 g of
RNA using Moloney murine leukemia virus reverse transcrip-
tase (Promega). Sybr-Green based real-time RT-PCR was per-
formed using a Roche-480 Light Cycler in a volume of 10 l
containing 50 ng of reverse transcribed cDNA and 5 ng of for-
ward and reverse primers for rat-Gck (forward, GATACCTG-
GGGAACAGCAAA; reverse, TAGGTGGAGACCCTGCT-
GAT); rat G6pc (forward, CTACCTTGCGGCTCACTTTC;
reverse, ATCCAAGTGCGAAACCAAAC); rat Pklr (forward,
CTGGAACACCTCTGCCTTCTG; reverse, CACAATTTCC-
ACCTCCGACTC); mouse Nnt (forward, GGAAGGGTCAG-
TTGTTGTGG; reverse, CCGGCTTAGTCGTTTCAAAG);
mouseGapdh (forward, GACAATGAATACGGCTACAGCA;
reverse, GGCCTCTCTTGCTCAGTGTC); mouse G6pc (for-
ward, TGGTAGCCCTGTCTTTCTTT; reverse, TCAGTTT-
CCAGCATTCACAC); mouse Txnip (forward, AACATCCC-
AGATACCCCAGA; reverse, GTGGGGCTCTCTAGTC-
TGTGA); mouse Gpd2 (forward, ACTACCTGAGTTCTGA-
CGTTGAAG; reverse, TAACAAGGGGACGGATACCA);
mouse ChREBP- (forward, CGACACTCACCCACCTC-
TTC; reverse, TTGTTCAGCCGGATCTTGTC); and mouse
ChREBP- (forward, TCTGCAGATCGCGTGGAG; reverse,
CTTGTCCCGGCATAGCAAC).
Statistical analysis
The results are expressed as means S.E. for the number of
hepatocyte preparations indicated in the legends. Statistical
analysis was by Student’s t test or by analysis of variance.
Author contributions—T.M., S. S. C., B. E. F., S. M., A. A., N. S. A.-P.,
M. C., and L. A. formal analysis; T. M., S. S. C., B. E. F., S. M., A. A.,
N. S. A.-P., C. A., Z. H. A.-O., M. F., B. V., M. C., and L. A. investiga-
tion; T. M., S. S. C., B. E. F., S. M., A. A., N. S. A.-P., M. C., and L. A.
visualization; T. M., S. M., andL. A.writing-review and editing; S. M.
and L. A. conceptualization; C. A., Z. H. A.-O., M. C., and L. A.
supervision; M. C. and L. A. funding acquisition; S. S. C., B. E. F.,
S. M., A. A.,M. F., B. V.,M. C., and L. A.methodology; L. A. writing-
original draft; L. A. project administration; M. F., B. V., M. C., and
L. A. resources.
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